Overview

Dose Optimisation Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to establish what dose level and dosing frequency is optimal in the treatment of rheumatoid arthritis patients with ART621.
Phase:
Phase 2
Details
Lead Sponsor:
Arana Therapeutics Ltd
Collaborator:
Trident Clinical Research Pty Ltd
Treatments:
Methotrexate